MedTrace Logo

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

NCT06686108 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-05-07

No results posted yet for this study

Summary

This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.

Conditions

  • T-cell Acute Lymphoblastic Leukemia
  • ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
  • Relapse

Interventions

DRUG

Azacitidine (AZA) Days 1 - 5

Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle

DRUG

Decitabine (DAC)

decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.

DRUG

Venetoclax

venetoclax, 400mg/d, days 1-7 of each 28-day cycle

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2027-10-30
Completion
2028-10-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686108 on ClinicalTrials.gov